A healed rat tendon leaves a human question.
“Better healing” sounds good. We want to know what healed, in whom, and compared with what. A stronger rat tendon and a person getting back to an ordinary day aren’t the same answer.
BPC-157 and TB-500 show why those details matter. We can take an animal finding seriously while keeping the human question open.
Getting back to ordinary movement
In one experiment, BPC-157 helped rats’ cut Achilles tendons heal faster and stronger. That tells us about an injury created for a study. It doesn’t tell us how much sooner a person with an everyday injury could climb stairs comfortably.
Here is the human Achilles in an ordinary movement. A photograph of a heel cannot turn a result from injured rat tendons into evidence of human healing.
We don’t have a reliable animal headcount or the full spread of results in the study summary. We leave those details unknown. Naming the species is useful; it doesn’t fill in the rest.
A few human reports don’t settle it
The FDA counted five human BPC-157 studies, with fewer than 100 people receiving it. Only two had comparison groups, and neither had been published as a full paper.
A comparison group helps us ask what might have happened without the treatment. Adding up people from different studies can’t create that missing comparison. It also can’t show us how much their experiences differed.
A similar name isn’t the same substance
The FDA found no published studies giving TB-500 to people. TB-500 is a short piece of thymosin beta-4, not the full protein. Findings about the full protein can’t simply be handed over to the fragment.
The same review found no animal study showing TB-500 heals wounds. In a test of a scratched layer of cells, it didn’t speed closure. That doesn’t prove it could never work; it leaves the human healing claim unanswered.
Unknown safety isn’t a clean bill of health
The BPC-157 reports covered small groups over short periods, and most left their safety monitoring unclear. That cannot establish safety. TB-500’s human risks also remain unknown. That’s part of the evidence, even if it’s less exciting than a recovery claim.
The FDA raises concerns about possible immune reactions to BPC-157 and possible immune reactions to TB-500. These are potential risks, not measured rates of harm in people.
On its page current as of April 22, 2026, the FDA lists both as nominated but withdrawn. That means the requests were taken back. It doesn’t mean FDA approval, clearance or permission to compound them.
An injury needs assessment by a licensed U.S. clinician. We can’t turn these findings into a recovery plan. For another example of a result with a limit, read about cells and people.